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**1. You are a consultant advising an HMO regarding the percentage of hepatitis E among US patients with hepatitis. Based on the study by Dr. Drobeniuc and colleagues, which of the following statements would most likely appear in your report?**

A. Hepatitis E was present in more than half of patients who were seronegative for acute hepatitis A and B

B. Among patients with hepatitis E, only one quarter had recently traveled abroad

C. Among patients with hepatitis E, half the patients had acute and half the patients had chronic hepatitis

D. Hepatitis E virus (HEV) infection was determined by testing for IgM and IgG anti-HEV and for HEV RNA

**2. Based on the study by Dr. Drobeniuc and colleagues, which of the following statements about group characteristics of nontravelers vs travelers with hepatitis E is most likely correct?**

A. Nontravelers were older than travelers

B. Nontravelers were more likely than travelers to be jaundiced

C. Nontravelers comprised fewer South Asians than travelers

D. Nontravelers were less likely than travelers to be solid organ transplant recipients

**3. Based on the study by Dr. Drobeniuc and colleagues, which of the following statements about HEV genotypes among nontravelers vs travelers with hepatitis E is most likely correct?**

A. Nontravelers were infected exclusively by HEV genotype 1 strains

B. Nontravelers were infected by HEV genotype 3 and 4 strains

C. Travelers were infected exclusively by HEV genotype 3 strains

D. The findings suggest that the nontravelers were infected by HEV that was circulating autochthonously in the United States.
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Hepatitis E in Africa, southern and central Asia, and Central America causes occasional outbreaks of jaundice and, between outbreaks, occurrences of sporadic jaundice. Primarily spread by waterborne transmission, the disease tends to resolve spontaneously, although fulminant hepatic failure can ensue ([@R-2-1]). In eastern Asia and Europe, sporadic hepatitis E, whether imported after return from international travel or acquired indigenously, has been observed; the indigenous form is thought to be foodborne ([@R-2-2]). Although the disease is largely self-limiting, in Europe, chronic hepatitis E, which may lead to cirrhosis, is increasingly recognized among solid-organ transplant recipients (SOTRs) ([@R-2-3]).

The causative agent of hepatitis E is hepatitis E virus (HEV), of which 4 genotypes are found in humans. Genotypes 1 and 2 circulate in regions where waterborne transmission is common; genotype 3 is prevalent in eastern Asia and the West and genotype 4 in eastern Asia. Genotypes 1 and 2 infect humans, but genotypes 3 and 4 infect humans and animals, predominantly pigs ([@R-2-4]).

In the United States, HEV imported into the country after travel to regions to which waterborne HEV transmission is endemic is well recognized ([@R-2-5]--[@R-2-7]). Recently, 21% of participants of the US-based Third National Health and Nutrition Examination Survey were found seropositive for IgG against HEV ([@R-2-8]). This unexpectedly high prevalence rate would not be ascribable to imported HEV infection alone. Indeed, cases of hepatitis E unassociated with travel abroad have been observed in the United States, implying infection by indigenous HEV strains ([@R-2-9]--[@R-2-14]). Moreover, the increasing number of reports from Europe of hepatitis E among SOTRs ([@R-2-3],[@R-2-15]) suggests that SOTRS in the United States might be similarly susceptible to the disease.

We report a study of demographic, clinical, travel-related, and virologic characteristics of persons with hepatitis E derived from a diverse patient base. Critical to this investigation was the application of a validated serologic assay for detecting IgM against HEV ([@R-2-16]), the marker of recent HEV infection, as well as a real-time reverse transcription PCR (RT-PCR) that had been validated to detect, to high sensitivity, HEV RNA ([@R-2-17]), which is an indicator of active HEV shedding. Together, these 2 assays enabled us to identify patients with incident hepatitis E.

Methods
=======

Samples and Patients
--------------------

The Centers for Disease Control and Prevention (CDC) conducts HEV testing of serum and stool samples referred by health care providers, public health departments, and diagnostic laboratories in the United States ([@R-2-18]). Referrers are requested to fill out a standardized questionnaire of patients' demographics, clinical and laboratory test features, and risks for HEV infection, including recent international travel and destinations visited; the completed questionnaire is submitted along with the test specimens ([@R-2-18]). Persons whose specimens were received during June 2005--March 2012 and reported as being negative for IgM against hepatitis A virus and hepatitis B core antigen, regardless of positivity for IgG against hepatitis C virus, were considered for inclusion into the study.

Assays
------

An earlier, pangenotypic evaluation by CDC of 6 serologic assays for IgM against HEV identified the assay manufactured by Diagnostic Systems (Saronno, Italy) as having the best performance characteristics ([@R-2-16]). Its diagnostic sensitivity and specificity were 98% and 95.2%, respectively, and its analytic sensitivity was 9 Walter Reed Units/mL. For this study, the assay was used to detect IgM against HEV in test samples. IgG against HEV was tested by applying an assay from the same manufacturer. Serum and stool samples were tested for HEV RNA by a real-time RT-PCR, capable of detecting HEV genotypes 1--4 to a sensitivity of 4 HEV genome-equivalents/mL, to amplify a 69-bp fragment in open reading frame (ORF) 3 of the HEV genome ([@R-2-19]). Application of that assay enabled our laboratory to attain perfect detection scores in a recent international evaluation of 20 laboratories conducting HEV RNA testing ([@R-2-17]). Samples found to be positive for HEV RNA were subjected to another RT-PCR to generate amplicons from a 258-bp segment from ORF1, which were then processed for nucleotide sequencing and phylogenetic analyses ([@R-2-20]).

Statistics
----------

Distributions of variables were assessed by using the Kruskal-Wallis test and the χ^2^ test with the Yates correction or the Fisher exact test, as appropriate. Univariate and bivariate data analyses were conducted by using Epi Info ([wwwn.cdc.gov/EpiInfo/html/prevVersion.htm](file:///\\\\\\\\cdc\\\\project\\\\CCID_NCPDCID_DEISS_EIDJ\\\\EID%20Production\\\\Production\\\\Vol19No02\\\\XML\\\\Word\\\\HOLD%20-%20CME%20Press\\\\wwwn.cdc.gov\\\\EpiInfo\\\\html\\\\prevVersion.htm)).

Case Definition
---------------

A case of hepatitis E was defined as illness in a person in whom IgM and IgG against HEV in serum or HEV RNA in serum or stool samples were detected. A person in whom IgM but not IgG against HEV was detected in serum was excluded unless HEV RNA was found or IgG againstHEV was detected in follow-up serum samples. A person in whom IgG but not IgM against HEV was detected in serum samples was included if HEV RNA was found in serum or stool samples.

Results
=======

Of 154 persons whose specimens fulfilled the inclusion criteria, 26 (17%) met the case definition for hepatitis E. Case-patients were between 14--67 years of age (median 43 years); 19 (73%) were male. Fifteen (58%) were white, 9 (36%) South Asian, and 2 (8%) Hispanic. None were seropositive for IgG against HEV. Eighteen (69%) case-patients were jaundiced, and 7 (27%) were SOTRs, the allografts received being kidney (3), liver (2), kidney and pancreas (1), and heart and lungs (1). Fifteen case-patients (58%) who reported not having traveled outside the United States in the previous 2 months were classified as nontravelers; the remaining 11, who had traveled abroad, were classified as travelers.

The [Table](#T-2-1){ref-type="table"} summarizes the demographic, clinical, and virologic data for individual case-patients. Compared with travelers, nontravelers were older (median age 61 vs. 32 years of age; p\<0.05) and more likely to be anicteric (not jaundiced; 8/15 \[53%\] vs. 1/11 \[8%\]; p = 0.02). The nontraveler group also included fewer South Asians (1/15 \[7%\] vs. 8/11 \[73%\]; p\<0.001) and more SOTRs (7/15 \[47%\] vs. 0; p = 0.02). Differences in sex distribution were not significant.

###### Demographic, clinical, travel-related, and virologic characteristics for patients with hepatitis E, United States, 2005--2012\*

  Travel history and case-patient no.   Age, y/sex   Race/ ethnicity   State of residence   Transplant (organ)          Jaundice   Countries visited       Anti-HEV SCR   HEV genotype   HEV viral load†   
  ------------------------------------- ------------ ----------------- -------------------- --------------------------- ---------- ----------------------- -------------- -------------- ----------------- -------------
  No recent international travel‡                                                                                                                                                                          
  NT1                                   61/M         White             FL                   No                          Yes        NA                      7.5            5.7            3                 NA
  NT2                                   45/M         White             CA                   No                          Yes        NA                      3.7            4              --                --
  NT3                                   63/M         White             SD                   Yes (kidney)                No         NA                      7.2            5.4            3                 NA
  NT4                                   61/M         South Asian       IL                   Yes (liver)                 No         NA                      1.9            5.9            3                 NA
  NT5                                   67/M         White             FL                   No                          Yes        NA                      6.3            1.3            --                --
  NT6                                   44/F         Hispanic          TX                   No                          Yes§       NA                      3.1            3.7            3                 NA
  NT7                                   21/F         Hispanic          TX                   No                          Yes¶       NA                      2.2            1.6            --                --
  NT8                                   67/M         White             IL                   Yes (heart and lungs)       Yes        NA                      3              3.3            --                --
  NT9                                   42/M         White             WI                   No                          Yes        NA                      6              6.6            --                --
  NT10                                  62/F         White             IL                   Yes (kidney)                No         NA                      2.9            8.9            --                --
  NT11                                  26/M         White             PA                   Yes (kidney)                No         NA                      5.3            8.3            3                 7.8 × 10^2^
  NT12                                  40/F         White             NY                   Yes (kidney and pancreas)   No\#       NA                      7.7            12.9           3                 1.4 × 10^3^
  NT13                                  64/M         White             CT                   Yes (liver)                 Yes        NA                      9.2            1.3            3                 1.4 × 10^4^
  NT14                                  29/F         White             MI                   No                          No\*\*     NA                      6.6            9.8            --                --
  NT15                                  62/M         White             NY                   No                          No         NA                      Neg            9.6            3                 1.5 × 10^3^
  Recent international travel‡                                                                                                                                                                             
  T1                                    35/M         South Asian       DE                   No                          Yes        India                   2.3            4.5            1                 1.8 × 10^2^
  T2                                    14/F         South Asian       TX                   No                          Yes        India                   7.3            5.8            --                --
  T3                                    32/F         South Asian       TX                   No                          Yes        India                   3.7            5.8            --                --
  T4                                    24/M         South Asian       TX                   No                          Yes        India                   2.3            2              --                --
  T5                                    35/M         White             IL                   No                          No         India and Indonesia     2.9            8.9            --                --
  T6                                    24/M         White             MD                   No                          Yes        Afghanistan and Dubai   6.9            9.4            --                --
  T7                                    63/M         White             AL                   No                          Yes        China                   7.9            Neg            4                 2.4 × 10^2^
  T8                                    23/M         South Asian       ME                   No­­                        Yes        Bangladesh              7.6            10.8           --                --
  T9                                    53/M         South Asian       MD                   No                          Yes††      India                   9.2            9.4            --                --
  T10                                   66/M         South Asian       TX                   No                          Yes        India                   5.5            11.7           1                 1.8 × 10^2^
  T11                                   22/M         South Asian       MD                   No                          Yes        India                   9.9            10.9           1                 8.3 × 10^5^

\*HEV, hepatitis E virus; SCR, signal/cutoff ratio; NT, nontraveler; NA, not applicable (quantitative reverse transcription PCR not done); --, HEV not detected or genotype not tested; Neg, negative. †In genome-equivalents/mL. ‡Within 2 mo before illness or visit to physician. §Fulminant hepatic failure developed but resolved ([@R-2-14]). ¶Fulminant hepatic failure developed; patient died at time of liver transplantation ([@R-2-14]). \#Initial illness was meningitis. \*\*Asymptomatic; tested for HEV because of recent miscarriage. ††Fulminant hepatic failure developed, requiring liver transplantation; patient survived.

Three case-patients (NT6, NT7, and T9; Tabl[](#T-2-1){ref-type="table"}e) were documented to have fulminant hepatic failure. Two of them required liver transplantation; 1 died and 1 survived.

HEV RNA was amplified from 12 case-patients (46%). The rate of HEV RNA detection among SOTRs (5/7; 71%) was higher than that among non-SOTRs (7/19; 37%), but this difference was not significant. HEV genotype 1 was characterized from 3 travelers, genotype 3 from 8 nontravelers (including the 5 SOTRs), and genotype 4 from 1 traveler. The [Figure](#F-2-1){ref-type="fig"} displays the genetic diversity of HEV carried.

![Genetic relatedness among hepatitis E virus (HEV) strains identified in hepatitis E cases, United States. Phylogenetic tree was constructed from a segment of HEV open reading frame 1 generated in MEGA5 ([www.megasoftware.net](file:///\\\\\\\\cdc\\\\project\\\\CCID_NCPDCID_DEISS_EIDJ\\\\EID%20Production\\\\Production\\\\Vol19No02\\\\XML\\\\Word\\\\HOLD%20-%20CME%20Press\\\\www.megasoftware.net)) by using the neighbor-joining method. Country, year reported, and numeric or GenBank accession number assignment are denoted. Scale bar indicates genetic distance.](12-0961-F){#F-2-1}

Discussion
==========

We identified 26 case-patients with hepatitis E in the United States. No distinction was made between acute and chronic hepatitis E. Whereas acute hepatitis among non-SOTRs was readily identifiable (most were jaundiced when test specimens were drawn), it was difficult to asses whether disease in SOTRs was at the acute or chronic stage during specimen sampling, because positivity for IgM against HEV or HEV RNA could reflect either stage ([@R-2-3]). Thus, the case definition was kept broad to identify both stages of disease. As the study was not primarily prospective, the natural history of hepatitis E among the case-patients was largely unknown. Nevertheless, adverse outcomes could be documented for 3 case-patients, in whom fulminant hepatic failure developed.

Hepatitis E cases were found among persons who had not recently traveled abroad and those who had. Nontravelers tended to be older than travelers, a trend consistent with the finding recently reported by the Drug-Induced Liver Injury Network of 9 patients seropositive for IgM against HEV whose mean age was 67 years ([@R-2-21]) and with similar observations in Japan and Europe ([@R-2-1],[@R-2-2],[@R-2-22]). The higher proportion of anicteric persons in the nontraveler group reflects its inclusion of all SOTRs, which in Europe have been observed to have largely asymptomatic infections ([@R-2-3]).

Nontravelers were infected exclusively by HEV genotype 3 strains. These strains clustered with HEV previously found in case-patients with nonimported acute hepatitis E ([@R-2-9]--[@R-2-12],[@R-2-14]) in the United States ([Figure](#F-2-1){ref-type="fig"}), suggesting that the nontravelers were infected by autochthonously circulating HEV. The similarity between HEV genotype 3 strains identified in nontravelers with those in swine ([@R-2-4]) ([Figure](#F-2-1){ref-type="fig"}) suggests, but does not prove, HEV transmission linkage between humans and pigs ([@R-2-2]). Evidence of HEV infection acquired after consumption of inadequately cooked meat and offal originating from pigs, boars, and deer has been reported from Japan ([@R-2-2]) and France ([@R-2-23]). Elsewhere, including the United States, evidence implicating non--travel-associated hepatitis E as a zoonosis remains weak ([@R-2-24]).

The patient base from which hepatitis E cases were identified was nonselective, broad, and derived from multiple health care provider contexts. Nonetheless, data from this study were not generated from an established, systematic program of epidemiologic surveillance. Accordingly, the cases identified here may not fully represent the extent of hepatitis E in the United States. The larger number of cases among nontravelers likely reflects more persons living in the United States who do not travel abroad compared with those who do, and the many SOTRs identified with hepatitis E could be an overrepresentation resulting from increasing awareness among physicians of the predilection of the SOTR patient subpopulation to HEV infection ([@R-2-3],[@R-2-15]). Future surveillance of hepatitis E may need to sample source populations from more diverse settings, such as gastroenterology/hepatology clinics ([@R-2-21]), travel clinics ([@R-2-6]), and the military ([@R-2-7]). We recently reported findings from a study of HEV infection among immunocompromised patients other than SOTRs ([@R-2-25]).

This study has provided insight into nonimported and imported hepatitis E in the United States. The nonimported form was observed to affect SOTRs, be able to lead to adverse outcomes, and be associated with infection by HEV genotype 3. The extent of nonimported hepatitis E in the United States merits further investigation, as does the role of autochthonous transmission of genotype 3 HEV strains. In clinical practice, entry of hepatitis E into the differential diagnosis of suspected hepatitis, regardless of the patient's travel history, would be appropriate.
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